Behavior modification

Better Therapeutics, Inc. to Present at the Canaccord Genuity’s 41st Annual Growth Conference

Retrieved on: 
Wednesday, August 4, 2021
Mental Health, Mobile, Wireless, Technology, Diabetes, Cardiology, Software, Other Health, Biotechnology, General Health, Health, Health sciences, Medicine, Articles, Health informatics, Behavior modification, Digital therapeutics, Addiction, Addiction medicine, Genuity, Therapy, Cognitive behavioral therapy, Disease, Better Therapeutics, Mountain Crest Acquisition Corp. II, BETTER THERAPEUTICS, MOUNTAIN CREST ACQUISITION CORP. II

Better Therapeutics, Inc. (Better Therapeutics), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is participating in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021.

Key Points: 
  • Better Therapeutics, Inc. (Better Therapeutics), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is participating in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021.
  • The cognitive behavioral therapy delivered by Better Therapeutics PDTs enables changes in neural pathways of the brain so lasting changes in behavior become possible.
  • Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs.
  • Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.

Cognito Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2021

Retrieved on: 
Wednesday, August 4, 2021
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Mental Health, Other Science, Research, Software, Science, Clinical Trials, Behavior modification, Digital therapeutics

Cognito Therapeutics , a Phase 3-ready disease-modifying digital therapeutics company developing a new category of therapeutic treatments for neurodegenerative diseases starting with Alzheimers Disease, today announced that Brent Vaughan, CEO, will participate in a fireside chat at the BTIG Biotechnology Conference 2021 on Monday, August 9, 2021 from 11:00-11:25 am ET.

Key Points: 
  • Cognito Therapeutics , a Phase 3-ready disease-modifying digital therapeutics company developing a new category of therapeutic treatments for neurodegenerative diseases starting with Alzheimers Disease, today announced that Brent Vaughan, CEO, will participate in a fireside chat at the BTIG Biotechnology Conference 2021 on Monday, August 9, 2021 from 11:00-11:25 am ET.
  • BTIG hosted events are intended for prospective and existing BTIG clients only.
  • To listen to the live event, please contact your BTIG representative.
  • Cognito Therapeutics is a clinical-stage company developing a pipeline of disease-modifying digital therapeutics targeting neurodegenerative disorders.

DarioHealth Behavioral Health Solution Selected by National Employer

Retrieved on: 
Wednesday, August 4, 2021
Articles, Health informatics, Health, Telehealth, Behavior modification, Digital therapeutics, Mental health, Digital health

NEW YORK, Aug. 4, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it has been selected as the digital behavioral health provider by a leading national professional services company.

Key Points: 
  • NEW YORK, Aug. 4, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it has been selected as the digital behavioral health provider by a leading national professional services company.
  • This new contract represents the fourth employer to partner with Dario for its digital behavioral health services in the last month as improving access to mental health resources remains a top priority.
  • "We are seeing significant interest in our behavioral health solution as employers increasingly find value in our ability to triage and treat for a wide range of needs.
  • Dario continues to nurture a healthy pipeline of employer clients looking for solutions to improve access and improve outcomes on a cost effective basis through digital health solutions, including in behavioral health.

Pear Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, August 3, 2021
Software, Biotechnology, Pharmaceutical, General Health, Health, FDA, Technology, Clinical trials, Health informatics, Behavior modification, Digital therapeutics

Pear Therapeutics, Inc. today announced managements participation in the following virtual investor conferences in August 2021:

Key Points: 
  • Pear Therapeutics, Inc. today announced managements participation in the following virtual investor conferences in August 2021:
    BTIG Biotechnology Conference.
  • Corey McCann, M.D., Ph.D., President and CEO, will participate in an analyst-led fireside chat at this virtual conference on Tuesday, August 10, 2021, at 3:30 p.m. Eastern Time.
  • Pear Therapeutics is a privately held, prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious disease.
  • Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs.

Better Therapeutics and Colorado Prevention Center Clinical Research Launch Real-World Evidence Study of Prescription Digital Therapeutic for Type 2 Diabetes

Retrieved on: 
Thursday, July 29, 2021
Software, Pharmaceutical, Health, Diabetes, Data management, Technology, Clinical trials, Mobile, Wireless, Behavior modification, Digital therapeutics, Colorado Prevention Center (CPC) Clinical Research, Better Therapeutics, Mountain Crest Acquisition Corp. II, COLORADO PREVENTION CENTER (CPC) CLINICAL RESEARCH, BETTER THERAPEUTICS, MOUNTAIN CREST ACQUISITION CORP. II

BT-001 is an investigational, prescription digital therapeutic that delivers a novel form of cognitive behavioral therapy to patients with uncontrolled type 2 diabetes.

Key Points: 
  • BT-001 is an investigational, prescription digital therapeutic that delivers a novel form of cognitive behavioral therapy to patients with uncontrolled type 2 diabetes.
  • The open-label, randomized, controlled study will evaluate approximately 500 patients with type 2 diabetes in the University of Colorado (UC) Health System using BT-001.
  • At Better Therapeutics, we believe the system of care desperately needs therapeutics that address the root causes of disease, said Mark Berman, MD, Chief Medical Officer of Better Therapeutics.
  • BT-001 is Better Therapeutics lead product candidate among their pipeline of FDA-regulated, prescription digital therapeutics designed to treat the underlying cause of a range of cardiometabolic conditions.

MedRhythms Closes $25M Series B Funding Led by Morningside Ventures and Advantage Capital to Advance Digital Therapeutics Platform

Retrieved on: 
Wednesday, July 28, 2021
Music, Physical therapy, Technology, Professional services, Health, Venture capital, Entertainment, Medical devices, Software, Audio, Video, Hardware, Health, Medical specialties, Behavior modification, Digital therapeutics, Physical therapy

MedRhythms digital therapeutic platform is designed to digitize an evidence-based intervention known as Rhythmic Auditory Stimulation, which uses music to target neural circuitry that controls movement.

Key Points: 
  • MedRhythms digital therapeutic platform is designed to digitize an evidence-based intervention known as Rhythmic Auditory Stimulation, which uses music to target neural circuitry that controls movement.
  • We are delighted to welcome a top-tier group of leading healthcare investors that will support the company to advance development of our pipeline of prescription digital therapeutics.
  • MedRhythms has developed a powerful digital therapeutics platform founded on the premise that targeting electrophysiological networks in the brain can be broadly effective against neurologic disorders, said Stephen Bruso of Morningside Ventures.
  • MedRhythms is a digital therapeutics company that uses sensors, music and software to build evidence-based neurologic interventions to measure and improve walking.

Biospectal Raises $4.3M Seed Funding Led by Digital Health Investor, SeedLink

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Biology, Health informatics, Articles, Biomarkers, Behavior modification, Digital therapeutics, Yamaha DTX series, Digital health, IOS, DTX

Remote patient monitoring and biosensing company will use investment to scale its OptiBP™ blood pressure measurement and monitoring product and operations worldwide; Renowned interventional cardiologist and inventor, Dr. Fred St. Goar, MD and SeedLink's Tim Juergens appointed to Biospectal's Board of Directors

Key Points: 
  • Biospectal will leverage the new funds to scale its OptiBPsmartphone blood pressure monitoring application and data platform technology worldwide.
  • Biospectal OptiBP for iOS is currently in alpha and is planned for public beta launch in the second half of 2021.
  • OptiBP's data also connects seamlessly with clinicians to support treatment regimens that help improve health and quality of life.
  • SeedLink SL supports founders in successfully establishing and growing solutions in the Digital Health space, with special focus on Digital Therapeutics (DtX), Digital Biomarkers, and platform-based business models.

Biospectal Raises $4.3M Seed Funding Led by Digital Health Investor, SeedLink

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Biology, Health informatics, Articles, Biomarkers, Behavior modification, Digital therapeutics, Yamaha DTX series, Digital health, IOS, DTX

LAUSANNE, Switzerland and SAN FRANCISCO, July 21, 2021 /PRNewswire/ -- Biospectal SA, the remote patient monitoring and biosensing software company, today announced the closing of a $4.3M (€3.7M Euros) round of seed funding led by digital health investor, SeedLink, with additional funding from LabCorp, Athensmed, Swiss based Privilege Ventures and other European and US investors. Biospectal will leverage the new funds to scale its OptiBP™ smartphone blood pressure monitoring application and data platform technology worldwide. Biospectal OptiBP for Android launched in public beta in January 2021. Biospectal OptiBP for iOS is currently in alpha and is planned for public beta launch in the second half of 2021. View a short video of how Biospectal OptiBP works here.

Key Points: 
  • Biospectal will leverage the new funds to scale its OptiBPsmartphone blood pressure monitoring application and data platform technology worldwide.
  • Biospectal OptiBP for iOS is currently in alpha and is planned for public beta launch in the second half of 2021.
  • OptiBP's data also connects seamlessly with clinicians to support treatment regimens that help improve health and quality of life.
  • SeedLink SL supports founders in successfully establishing and growing solutions in the Digital Health space, with special focus on Digital Therapeutics (DtX), Digital Biomarkers, and platform-based business models.

United States Digital Therapeutics Market Research Report 2021-2026 with Cumulative Impacts of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Software, Technology, General Health, Health, Behavior modification, Digital therapeutics

The "Digital Therapeutics Market Research Report by Indication, by Distribution, by State - United States Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Digital Therapeutics Market Research Report by Indication, by Distribution, by State - United States Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
  • The United States Digital Therapeutics Market is projected to grow with a significant CAGR in the forecast period.
  • Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Digital Therapeutics Market.
  • The ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward.

Medisafe Expands Patient-Clinician Connectivity with New Digital Tools

Retrieved on: 
Thursday, July 15, 2021
Health informatics, Articles, Behavior modification, Digital therapeutics, ISO/IEC 27001, Interoperability, Computing, Technology

BOSTON, July 15, 2021 /PRNewswire/ -- Medisafe , a leading evidence-based digital therapeutics company, is expanding its connectivity and interoperability among nurse teams and patient support services with its new Care Widgets.

Key Points: 
  • BOSTON, July 15, 2021 /PRNewswire/ -- Medisafe , a leading evidence-based digital therapeutics company, is expanding its connectivity and interoperability among nurse teams and patient support services with its new Care Widgets.
  • "This latest rollout is a part of our commitment to building the future model of patient support," said Omri Shor, co-founder and CEO of Medisafe.
  • Medisafe is the leading evidence-based digital therapeutics company providing medication management solutions across the healthcare continuum, a $300 billion problem in the US alone.
  • Medisafe is a HIPAA and GDPR compliant solution and ISO 27001:2013 certified.For more information, please visit www.medisafe.com .